# US 2001/0018524 A1 · Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0018524 A1
- Document ID: US20010018524A1
- Status: Published application
- Kind: A1
- Application number: 09/801,778
- Filed: 2001-03-09
- Published: 2001-08-30
- Earliest claimed: 1999-10-06
- Inventors: Alangudi Sankaranarayanan
- Web page: https://patentgrep.com/patent/US20010018524A1

## CPC

- A61K 31/4425: Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
- A61K 31/4436: containing a heterocyclic ring having sulfur as a ring hetero atom
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 213/77: Hydrazine radicals
- C07D 213/82: in position 3
- C07D 213/87: in position 3
- C07D 409/14: containing three or more hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological disorders and discoloration of teeth, by breaking preformed AGE, of the general formula I, or pharmaceutically acceptable salts thereof, 1 wherein, R1, R2, R3, X and m are as defined in the specification. Also disclosed is a method for preparation of the compounds of general formula (I) and pharmaceutical composition containing one or more compounds as defined above as active ingredients. Also disclosed is a method of treatment of a diabetic patient by administering the compounds as defined above, either singly or in combination with drugs for antidiabetic therapy.

## Claims

### Claim 1

A compound represented by general formula (I), and its pharmaceutically acceptable salts: 5
wherein
R1is -R4-R5or -N(R7) N (R7) R9;
R4is selected from the group consisting of -N(R7)R60-, -N(R7)R6N(R7),-OR 6O, and -OR6N(R7)-, where R6is alkyl;
R5is selected from the group consisting of alkyl, aryl including heteroaryl, -COR7, -SO2R7, -C(S) NHR7,-C(NH)NHR7, -COR10, 6
where R7is selected from the group consisting of H, alkyl and aryl including heteroaryl, provided R7may be the same or different for R and R3in the same compound;
R2is selected from the group consisting of F, Cl, Br, I, OR7, NO2, alkyl, aryl including heteroaryl, fornyl, acyl, C(O)NR7R10, C(O)OR7,NR7R10, N=C(R7)(R10), SR7, SO2NH2, SO2 alkyl and SO2aryl; m is 0, 1or 2;
R3is selected from the group consisting of R7, OR7, N(R7) R10), N=C(R7)(R10), N(R7) N(R7)(R10), N(R7)N=C(R7)(R10) and CH(R7)C(O)R8where R8is selected from the group consisting of R7, OR7 and NR7R10;
R9 is selected from the group consisting of hydrogen, alkyl, aryl including heteroaryl, C(O)R10, -SO2R10, C(S)NHR10, C(NH) NH (R10) and C(O) NHR10;
R10 is selected for the group consisting of H, alkyl and aryl, including heteroaryl and in each case may be the same or different from substituent R7, provided R10 may be the same or different for R1 and R3 in the same compound;
X is selected from group consisting of a halide ion, acetate ion, perchlorate ion, sulfonate ion, oxalate ion, citrate ion, tosylate ion, maleate ion, mesylate ion, carbonate ion, sulfite ion, phosphoric hydrogen ion, phosphonate ion, phosphate ion, BF4−and PF6−; with proviso that,
(i) when two alkyl groups are present on the same carbon or nitrogen, they may be linked together to form a cyclic structure, and
(ii) the nitrogen of heteroaryl ring of R10, when present, may be quaternized.

### Claim 2 (depends on 1)

The compound as claimed in claim 1, wherein -C(O)R1 group is at position 3 or 4.

### Claim 3 (depends on 2)

The compound as claimed in claim 2, wherein the position for -C(O)R1 group is at position 3.

### Claim 4 (depends on 1)

The compound as claimed in claims 1, wherein m is 0 or 1.

### Claim 5 (depends on 2)

The compound as claimed in claim 2, wherein m is 0 or 1.

### Claim 6 (depends on 3)

The compound as claimed in claim 3, wherein m is 0 or 1.

### Claim 7 (depends on 1)

The compound as claimed in claim 1, wherein m is 0.

### Claim 8 (depends on 2)

The compound as claimed in claim 2, wherein m is 0.

### Claim 9 (depends on 3)

The compound as claimed in claim 3, wherein m is 0.

### Claim 10 (depends on 1)

The compound as claimed in claim 1, wherein X is a halide ion.

### Claim 11 (depends on 1)

The compound as claimed in claim 1, which is selected from the group consisting of the following compounds:
(a) N,N′-bis[3-carbonyl-1-(2-thien -2′-yl-2-oxoethyl) -3-pyridinium] hydrazine dibromide and pharmaceutically acceptable salts thereof,
(b) 1-(2-ethoxy -2-oxoethyl) -3-(2-(2-pyridyl)hydrazinocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(c) 1-(2-ethoxy -2-oxoethyl) -3-(2-(benzoyloxy) ethylamino carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(d) N,N′-bis[3-carbonyl-1-(2-phenyl-2-oxoethyl)pyridinium]hydrazine dibromide and pharmaceutically acceptable salts thereof,
(e) 1-(2-phenyl-2-oxoethyl)-3-(hydrazinocarbonyl)pyridinium bromide and pharmaceutically acceptable salts thereof,
(f) 1-(2′-thien -2′-yl -2-oxoethyl) -3-(methanesulfonyl hydrazinocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(g)N,N′-bis[3-carbonyl-1-(2-(2′, 4′-dichlorophenyl)-2-oxoethyl) pyridinium] hydrazine dibromide and pharmaceutically acceptable salts thereof,
(h) 1-(2-phenyl -2-oxoethyl) -3-(methanesulfonyl hydrazinocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(i) 1-(2-ethoxy -2-oxoethyl) -3-(methanesulfonyl hydrazinocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(j) 1-(2-phenyl-2-oxoethyl)-3-(phenylsulfonylhydrazino carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(k) 1-(2-phenyl-2-oxoethyl)-2-chloro-3-(phenylsulfonyl hydrazino carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(l) 1-(2-thien -2′-yl -2-oxoethyl)-4-(2-(benzoyloxy) ethyl aminocarbonyl) pyridmium bromide and pharmaceutically acceptable salts thereof,
(m) 1-(2-(2,′,4′-dichlorophenyl) -2-oxoethyl) -3-(2-(benzoyloxy) ethylaminocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(n) 1-(2-phenyl -2-oxoethyl) -3-(2-(acetoxy) ethyloxy) carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(o) 1-(2-ethoxy -2-oxoethyl) -3-(2-(benzoyloxy) ethyloxy carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(p) 1-(2-phenylamino-2-oxoethyl)4-(phenylsulfonyl hydrazino carbonyl)pyridinium chloride and pharmaceutically acceptable salts thereof,
(q) 1-(2-(2,′,4′-dichlorophenyl)-2-oxoethyl)-3-(2(methoxy) ethyloxycarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(r) 1-(2-phenylamino-2-oxoethyl)-3-((benzoyloxy) ethylaminocarbonyl) pyridinium chloride and pharmaceutically acceptable salts thereof,
(s) 1-(2-thien-2′-yl-2-oxoethyl)-3-(phenylaminocarbonyl hydrazinocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(t) 1-(2-phenyl-2-oxoethyl)-3-(2-(acetoxy) ethylaminocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(u) 1-(2-phenylamino-2-oxoethyl)-3-(phenyl sulfonyl hydrazino carbonyl) pyridinium chloride and pharmaceutically acceptable salts thereof,
(v) 1-(2-phenylamino-2-oxoethyl)-3-((4-methylphenyl)sulfonyl hydrazinocarbonyl) pyridinium chloride and pharmaceutically acceptable salts thereof,
(w) 1-(2-phenyl-2-oxoethyl)-3-(2-(benzoyloxy)ethyloxy carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(x) 1-(2-thien-2′-yl-2-oxoethyl)-3-(phenylcarbonyl hydrazino carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(y) 1-(2-ethoxy-2-oxoethyl)-3-((phenylmethyl)sulfonyl hydrazino carbonyl)pyridinium bromide and pharmaceutically acceptable salts thereof and
(z) 1-(2-phenyl-2-oxoethyl)-3-((phenylmethyl)sulfonyl hydrazino carbonyl)pyridinium bromide and pharmaceutically acceptable salts thereof.

### Claim 12 (depends on 1)

The compound as claimed in claim 1, which is selected from the group consisting of the following compounds:
(aa) N,N′-bis [3-carbonyl-I-(2-furan-2′-yl-2-oxoethyl) pyridinium] hydrazine dibromide and pharmaceutically acceptable salts thereof,
(ab) N,N′-bis [3-carbonyl -1-(2-thien-2′-yl-2-oxoethyl) pyridinium] hydrazine dichloride and pharmaceutically acceptable salts thereof,
(ac) N,N′-bis-[3-carbonyl-1-(2-cyclopropylamino-2-oxoethyl) pyridinium] hydrazine dichloride and pharmaceutically acceptable salts thereof,
(ad) 1-(2′,4′-dichloro-phenyl-2-oxoethyl)-3-(2-methoxyethyl aminocarbonyl)-pyridinium bromide and, pharmaceutically acceptable salts thereof,
(ae) 1-(2-thien-2′-yl-2-oxoethyl)-3-((2-methoxy ethyl) amino carbonyl)-5-bromo pyridinium chloride and pharmaceutically acceptable salts thereof,
(af) 1-(2-thien-2′-yl-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride and pharmaceutically acceptable salts thereof,
(ag) 1-(2-thien-2′yl-2-oxoethyl)-3-(2-(2-chloro-3-pyridoylhydrazinocarbonyl)-pyridinium chloride and pharmaceutically acceptable salts thereof,
(ah) 1-(2-cyclopropylamino-2-oxoethyl)-3-(2-methoxyethylaminocarbonyl)-pyridinium chloride and pharmaceutically acceptable salts thereof,
(ai) 1(2-isopropylamino-2-oxoethyl)-3-(2-methylsulfonylhydrazinocarbonyl)-pyridinium chloride and pharmaceutically acceptable salts thereof,
(aj) 1-(2-phenylamino-2-oxo ethyl)-3-({2-(1-oxo-3-cyclohexyl)-propyl}-hydrazino-carbonyl)-pyridinium bromide and pharmaceutically acceptable salts thereof,
(ak) 1-(2-thien-2′-yl-2-oxoethyl)-3-[2-(benzoyloxy)ethylamino carbonyl]-pyridinium bromide and pharmaceutically acceptable salts thereof,
(al) 1-(4-ethoxy-2, 4-dioxobutyl)-3-(2-(benzoyloxy)ethylamino carbonyl)-pyridinium chloride and pharmaceutically acceptable salts thereof, and
(am) 1-(2-thien-2′-yl-2-oxoethyl)-3-[l-oxo-1-(2-methoxy carbonyl) pyridyl] hydrazino pyridinium chloride and pharmaceutically acceptable salts thereof.

### Claim 13 (depends on 1)

A process for the preparation of the compound represented by general formula (I) as claimed in claim 1, which comprises preparing a substituted pyridine, followed by quaternizing the substituted pyridine, with a quaternizing reagent in an alcoholic and/or high boiling solvent under reflux for 6-48hrs. to give the desired compound.

### Claim 14 (depends on 1)

The compound of general formula I as defined in claim 1, for use as a medicament in the treatment of diabetic complications and aging-related diseases.

### Claim 15 (depends on 1)

The compound of general formula (I), as defined in claim 1, for use as a medicament in the treatment of kidney disease, nerve damage, retinopathy, atherosclerosis, microangiopathy, endothelial dysfunctions, dermatological conditions and discoloration of teeth.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds represented by general formula (I), ad defined in claim 1 or pharmaceutically acceptable salt(s) thereof in admixture with a pharmaceutically acceptable carrier, diluent, solvent or excepient.

### Claim 17 (depends on 16)

The pharmaceutical composition as claimed in claim 16, in the form of an oral formulation.

### Claim 18 (depends on 16)

The pharmaceutical composition as claimed in claim 16, wherein said acceptable carier, diluent, solvent or excepient is selected from group consisting of starch, lactose, polyvinyl pyrolidone (K-30), talc and magnesium stearate.

### Claim 19 (depends on 16)

The pharmaceutical composition as claimed in claim 16 in the form of a parenteral formulation.

### Claim 20 (depends on 1, 19)

A method for the preparation of a parenteral formulation as claimed in claim 19, which comprises dissolving one or more compounds represented by general formula (I), as defined in claim 1, in polyethylene glycol 400 and diluting the solution so obtained, with an isotonic solution or water to a desired concentration.

### Claim 21 (depends on 16)

Pharmaceutical composition as claimed in claim 16, in the form of a lotion, oral rinse and toothpaste.

### Claim 22 (depends on 1)

A method for treating a diabetic patient by breaking a preformed AGE, within said patient, which comprises, administering an effective amount of a compound represented by general formula (I) as claimed in claim 1, either singly, or in combination with other drugs for antidiabetic therapy.

### Claim 23 (depends on 1)

A method of preventing or treating diseases caused by diabetes and aging related complications, which comprises, administering to a patient in need thereof, an effective amount of a compound represented by general formula (I), as claimed in claim 1, either singly or in combination with a pharmaceutically acceptable carrier, diluent or excepient.

### Claim 24 (depends on 23)

The method as claimed in claim 23, wherein the disease prevented or treated is a nephrological disorder, neurological disorder, atherosclerosis, retinal disorder, dermatological disorder, non-enzymatic browning of oral cavity, endothelial or other organ dysfunction and growth impairment.

### Claim 25 (depends on 22)

The method as claimed in claim 22, wherein said compound is selected from the group consisting of:
(a) N,N′-bis[3-carbonyl-1-(2-thien -2′-yl -2-oxoethyl) -3-pyridinium] hydrazine dibromide and pharmaceutically acceptable salts thereof,
(b) 1-(2-ethoxy -2-oxoethyl) -3-(2-(2-pyridyl)hydrazinocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(c) 1-(2-ethoxy -2-oxoethyl) -3-(2-(benzoyloxy)ethylamino carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(d) N,N′-bis[3-carbonyl-1-(2-phenyl-2-oxoethyl)pyridinium]hydrazine dibromide and pharmaceutically acceptable salts thereof,
(e) 1-(2-phenyl-2-oxoethyl)-3-(hydrazinocarbonyl)pyridinium bromide and pharmaceutically acceptable salts thereof,
(f) 1-(2-thien -2′-yl -2-oxoethyl) -3-(methanesulfonyl hydrazinocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(g) N,N′-bis [3-carbonyl -1-(2-(2′,4′-dichlorophenyl) -2-oxoethyl) pyridinium] hydrazine dibromide and pharmaceutically acceptable salts thereof,
(h) 1-(2-phenyl -2-oxoethyl) -3-(methanesulfonyl hydrazinocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(i) 1-(2-ethoxy -2-oxoethyl) -3-(methanesulfonyl hydrazinocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(j) 1-(2-phenyl-2-oxoethyl)-3-(phenylsulfonylhydrazinocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(k) 1-(2-phenyl-2-oxoethyl)-2-chloro-3-(phenylsulfonylhydrazino carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(l) 1-(2-thien -2′-yl -2-oxoethyl)-4-(2-(benzoyloxy) ethylaminocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(m) 1-(2-(2,4-dichlorophenyl)-2-oxoethyl)-3-(2-(benzoyloxy)ethylamino carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(n) 1-(2-phenyl -2-oxoethyl) -3-(2-(acetoxy) ethyloxy carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(o) l-(2-ethoxy -2-oxoethyl) -3-(2-(benzoyloxy) ethyloxy carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(p) 1-(2-phenylamino-2-oxoethyl)-4-(phenylsulfonyl hydrazino carbonyl) pyridinium chloride and pharmaceutically acceptable salts thereof,
(q) 1-(2-(2′,4′-dichlorophenyl)-2-oxoethyl)-3-(2(methoxy) ethyloxycarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(r) 1-(2-phenylamino-2-oxoethyl)-3-((benzoyloxy) ethylaminocarbonyl) pyridinium chloride and pharmaceutically acceptable salts thereof,
(s) 1-(2-thien-2′-yl-2-oxoethyl)-3-(phenylaminocarbonyl hydrazinocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(t) 1-(2-phenyl-2-oxoethyl)-3-(2-(acetoxy) ethylaminocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(u) 1-(2-phenylamino-2-oxoethyl)-3-(phenyl sulfonyl hydrazino carbonyl) pyridinium chloride and pharmaceutically acceptable salts thereof,
(v) 1-(2-phenylamino-2-oxoethyl)-3-((4-methylphenyl)sulfonyl hydrazino carbonyl) pyridinium chloride and pharmaceutically acceptable salts thereof,
(w) 1-(2-phenyl-2-oxoethyl)-3-(2-(benzoyloxy)ethyloxy carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(x) 1-(2-thien-2′-yl-2-oxoethyl)-3-(phenylcarbonyl hydrazino carbonyl) pyridmium bromide and pharmaceutically acceptable salts thereof,
(y) 1-(2-ethoxy-2-oxoethyl)-3-((phenylmethyl)sulfonyl hydrazino carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof and
(z) 1-(2-phenyl-2-oxoethyl)-3-((phenylmethyl) sulfonyl hydrazinocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,

### Claim 26 (depends on 22)

The method as claimed in claim 22, wherein said compound is selected from the group consisting of:
(aa) N,N′-bis [3-carbonyl-1-(2-furan-2′-yl-2-oxoethyl) pyridinium] hydrazine dibromide and pharmaceutically acceptable salts thereof,
(ab) N,N′-bis [3-carbonyl -1-(2-thien-2′-yl-2-oxoethyl) pyridinium] hydrazine dichloride and pharmaceutically acceptable salts thereof,
(ac) 1-(2-phenylamino-2-oxo ethyl)-3-({2-(1-oxo-3-cyclohexyl)- propyl} -hydrazino-carbonyl)-pyridinium bromide and pharmaceutically acceptable salts thereof, thereof,
(ae) 1-(4-ethoxy-2, 4-dioxobutyl)-3-(2-(benzoyloxy)ethylamino carbonyl)-pyridinium chloride and pharmaceutically acceptable salts thereof,
(af) 1-2′,4′ -dichloro-phenyl-2-oxoethyl)-3-(2-methoxyethyl aminocarbonyl)-pyridinium bromide and pharmaceutically acceptable salts thereof,
(ag) N,N′-bis-[3-carbonyl-1-(2-cyclopropylamino-2-oxoethyl) pyridinium] hydrazine dichloride and pharmaceutically acceptable salts thereof,
(ah) 1-(2-cyclopropylamino-2-oxoethyl)-3-(2-methoxyethylaminocarbonyl)-pyridinium chloride and pharmaceutically acceptable salts thereof,
(ai) 1-(2-thien-2′yl-2-oxoethyl)-3-(2-(2-chloro-3-pyridoylhydrazinocarbonyl)-pyridinium chloride and pharmaceutically acceptable salts thereof,
(aj) 1-(2-isopropylamino-2-oxoethyl)-3-(2-methylsulfonylhydrazinocarbonyl)-pyridinium chloride and pharmaceutically acceptable salts thereof,
(ak) 1-(2-thien-2′-yl-2-oxoethyl)-3-(methanesulfonylhydrazino carbonyl) pyridinium chloride and pharmaceutically acceptable salts thereof,
(al) 1-(2-thien-2′-yl-2-oxoethyl)-3-((2-methoxy ethyl) amino carbonyl)-5 -bromo pyridinium chloride and pharmaceutically acceptable salts thereof, and
(am) 1-(2-thien-2′-yl-2-oxoethyl)-3-[ 1-oxo-1-(2-methoxycarbonyl) pyridyl] hydrazino pyridinium chloride and pharmaceutically acceptable salts thereof.

### Claim 27 (depends on 23)

The method as claimed in claim 23, wherein said compound is selected from the group consisting of:
(a) N,N′-bis[3-carbonyl-1-(2-thien -2′-yl -2-oxoethyl) -3-pyridinium ]hydrazine dibromide and pharmaceutically acceptable salts thereof,
(b) 1-(2-ethoxy -2-oxoethyl) -3-(2-(2-pyridyl)hydrazinocarbonyl) pyridimium bromide and pharmaceutically acceptable salts thereof,
(c) 1-(2-ethoxy -2-oxoethyl) -3-(2-(benzoyloxy)ethylamino carbonyl) pyrdinium bromide and pharmaceutically acceptable salts thereof,
(d) N,N′-bis[3-carbonyl-1-(2-phenyl-2-oxoethyl)pyridinium]hydrazine dibromide and pharmaceutically acceptable salts thereof,
(e) 1-(2-phenyl-2-oxoethyl)-3-(hydrazinocarbonyl)pyridinium bromide and pharmaceutically acceptable salts thereof,
(f) 1-(2-thien -2′-yl -2-oxoethyl) -3-(methanesulfonyl hydrazinocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(g) N,N′-bis [3-carbonyl -1-(2-(2 ,41-dichlorophenyl) -2-oxoethyl) pyridinium] hydrazine dibromide and pharmaceutically acceptable salts thereof,
(h) 1-(2-phenyl -2-oxoethyl) -3-(methanesulfonyl hydrazinocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(i) 1-(2-ethoxy -2-oxoethyl) -3-(methanesulfonyl hydrazinocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(j) 1-(2-phenyl-2-oxoethyl)-3-phenylsulfonylhydrazinocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(k) -(2-phenyl-2-oxoethyl)-2-chloro-3-(phenylsulfonylhydrazino carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(l) 1-(2-thien -2′-yl -2-oxoethyl)-4-(2-(benzoyloxy) ethylaminocarbonyl) pyridimium bromide and pharmaceutically acceptable salts thereof,
(m) 1-(2-(2,4-dichlorophenyl)-2-oxoethyl)-3-(2-(benzoyloxy)ethylamino carbonyl) pyrdinium bromide and pharmaceutically acceptable salts thereof,
(n) 1-(2-phenyl -2-oxoethyl) -3-(2-(acetoxy) ethyloxy carbonyl) pyridmium bromide and pharmaceutically acceptable salts thereof,
(o) 1-(2-ethoxy -2-oxoethyl) -3-(2-(benzoyloxy) ethyloxy carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(p) 1-(2-phenylamino-2-oxoethyl)-4-(phenylsulfonyl hydrazino carbonyl) pyridmium chloride and pharmaceutically acceptable salts thereof,
(q) 1-(2-(2′,4′-dichlorophenyl)-2-oxoethyl)-3-(2(methoxy) ethyloxycarbonyl) pyridmium bromide and pharmaceutically acceptable salts thereof,
(r) 1-(2-phenylamino-2-oxoethyl)-3-((benzoyloxy) ethylaminocarbonyl) pyridinium chloride and pharmaceutically acceptable salts thereof,
(s) 1-(2-thien-2′-yl-2-oxoethyl)-3-(phenylaminocarbonyl hydrazinocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(t) 1-(2-phenyl-2-oxoethyl)-3-(2-(acetoxy) ethylaminocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(u) 1-(2-phenylamino-2-oxoethyl)-3-(phenyl sulfonyl hydrazino carbonyl) pyridinium chloride and pharmaceutically acceptable salts thereof,
(v) 1-(2-phenylamino-2-oxoethyl)-3-((4-methylphenyl)sulfonyl hydrazino carbonyl) pyridmium chloride and pharmaceutically acceptable salts thereof,
(w) 1-(2-phenyl-2-oxoethyl)-3-(2-(benzoyloxy)ethyloxy carbonyl) pyridiwum bromide and pharmaceutically acceptable salts thereof,
(x) 1-(2-thien-2′-yl-2-oxoethyl)-3-(phenylcarbonyl hydrazino carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,
(y) 1-(2-ethoxy-2-oxoethyl)-3-((phenylmethyl)sulfonyl hydrazino carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof and
(z) 1-(2-phenyl-2-oxoethyl)-3-((phenylmethyl) sulfonyl hydrazinocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof,

### Claim 28 (depends on 23)

The method as claimed in claim 23, wherein said compound is selected from the group consisting of:
(aa) N,N′-bis [3-carbonyl-1-(2-furan-2′-yl-2-oxoethyl) pyridinium] hydrazine dibromide and pharmaceutically acceptable salts thereof,
(ab) N,N′-bis [3-carbonyl -1-(2-thien-2′-yl-2-oxoethyl) pyridinium] hydrazine dichloride and pharmaceutically acceptable salts thereof,
(ac) 1-(2-phenylamino-2-oxo ethyl)-3-({2-(l-oxo-3-cyclohexyl)-propyl } -hydrazino-carbonyl)-pyridmium bromide and pharmaceutically acceptable salts thereof,
(ad) 1-(2-thien-2′-yl-2-oxoethyl)-3-[2-(benzoyloxy)ethylamino carbonyl]-pyridinium bromide and pharmaceutically acceptable salts thereof,
(ae) 1-(4-ethoxy-2, 4-dioxobutyl)-3-(2-(benzoyloxy)ethylamino carbonyl)-pyridinium chloride and pharmaceutically acceptable salts thereof,
(af) 1-(2′,4′-dichloro-phenyl-2-oxoethyl)-3-(2-methoxyethyl aminocarbonyl)-pyridinium bromide and pharmaceutically acceptable salts thereof,
(ag) N,N′-bis-[3-carbonyl-1-(2-cyclopropylamino-2-oxoethyl) pyridinium]hydrazine dichloride and pharmaceutically acceptable salts thereof,
(ah) 1-(2-cyclopropylamino-2-oxoethyl)-3-(2-methoxyethylaminocarbonyl)-pyrdinium chloride and pharmaceutically acceptable salts thereof,
(ai) 1-(2-thien-2′yl-2-oxoethyl)-3-(2-(2-chloro-3-pyridoylhydrazinocarbonyl)-pyridinium chloride and pharmaceutically acceptable salts thereof,
(aj) 1-(2-isopropylamino-2-oxoethyl)-3-(2-methylsulfonylhydraziocarbonyl)-pyridinium chloride and pharmaceutically acceptable salts thereof,
(ak) 1-(2-thien-2′-yl-2-oxoethyl)-3-(methanesulfonylhydrazino carbonyl) pyridinium chloride and pharmaceutically acceptable salts thereof,
(al) 1-(2-thien-2′-yl-2-oxoethyl)-3-((2-methoxy ethyl) amino carbonyl)-5 -bromo pyridinium chloride and pharmaceutically acceptable salts thereof, and
(am) 1-(2-thien-2′-yl-2-oxoethyl)-3-[1-oxo-1-(2-methoxycarbonyl) pyridyl] hydrazino pyridinium chloride and pharmaceutically acceptable salts thereof.
